Background-Data on sex difference in response to cardiac resynchronization therapy (CRT) remain controversial. We conducted a meta-analysis to summarize all published studies to determine whether sex-based differences in response to CRT exist. Methods and Results-We performed a literature search using MEDLINE (source PubMedwith no restrictions. Pooled effect estimates were obtained by using randomeffects meta-analysis. Seventy-two studies involving 33 434 patients were identified. Overall, female patients had better outcomes from CRT compared with male patients, with a significant 33% reduction in the risk of death from any cause (hazard ratio, 0.67; 95% confidence interval, 0.61-0.74; P<0.001), 20% reduction in death or hospitalization for heart failure (hazard ratio, 0.80; 95% confidence interval, 0.71-0.90; P<0.001), 41% reduction in cardiac death (hazard ratio, 0.59; 95% confidence interval, 0.42-0.84; P<0.001), and 41% reduction in ventricular arrhythmias or sudden cardiac death (hazard ratio, 0.59; 95% confidence interval, 0.49-0.70; P<0.001). These more favorable responses to CRT in women were consistently associated with greater echocardiographic evidence of reverse cardiac remodeling in women than in men. Conclusions-Women obtained greater reductions in the risk of death from any cause, cardiac cause, death or hospitalization for heart failure, and ventricular arrhythmias or sudden cardiac death with CRT therapy compared with men, with consistently greater echocardiographic evidence of reverse cardiac remodeling in women than in men. Further studies are needed to investigate the exact reasons for these results and determine whether indications for CRT in women should be different from men. (Circ Arrhythm Electrophysiol. 2014;7:807-815.)
C ardiac resynchronization therapy (CRT) has been shown to improve both survival and health-related quality of life in patients with heart failure (HF). However, women are poorly represented in clinical trials from which current standards of care and treatment guidelines of CRT are derived. 1 In fact, studies assessing sex differences in response to CRT showed conflicting results. For example, evidence from COMPANIAN (Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure) and REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) trials showed that women with HF might benefit the same as men from CRT for reduction in the risk of death or hospitalization for HF, 2,3 and a sex analysis in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) trial demonstrated that women with HF benefit more from CRT than similarly selected men. 4
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As such, we conducted a meta-analysis of CRT studies on the end points of death from any cause, death or hospitalization for HF, cardiac death and hospitalization for HF, and ventricular arrhythmias or sudden cardiac death in women compared with men.
Methods

Search Strategy and Selection Criteria
We did a computerized search of English-language publications listed in the electronic databases MEDLINE (source PUBMED; January 1966 to March 2014) and EMBASE (January 1980 to March 2014) using the following text and key words in combination both as Medical Subject Headings terms and text words: cardiac resynchronization, biventricular, CRT, heart failure, death, mortality, ventricular arrhythmia, ventricular tachycardia, sudden cardiac death, randomized controlled trial, cohort studies, prospective studies, sex, sex, men women male female.
To minimize differences between studies, we imposed the following methodological restrictions for the inclusion criteria: (1) cohort studies or randomized controlled studies that had a randomized design, October 2014 (2) tested CRT efficacy in HF patients with left ventricular ejection fraction (LVEF) ≤35% and QRS duration ≥120 ms, (3) reported an estimate of the risk for specified end points for women compared with men, adjusted for all possible baseline confounders or covariates.
Data Abstraction
Data on the following characteristics were independently extracted: author identification, year of publication, type of study design, study population, study protocol, device utilized, and hazard ratio (HR) with 95% confidence interval (CI) for sex. Death from any cause was the primary end point of interest. The second end point was a composite of death from any cause or hospitalization for HF. We also analyzed the outcomes of death from cardiac cause or hospitalization for HF.
Data Analysis
Summary HRs (95% CI) were calculated by pooling the study-specific estimates using a random-effects model that included between-study heterogeneity, because significant heterogeneity was anticipated among studies. Pooled HRs were expressed with 95% CIs. We calculated the I 2 (95% CI) statistic to assess heterogeneity across studies, applying the following interpretation for I 2 : <50%=low heterogeneity; 50% to 75%=moderate heterogeneity; >75%=high heterogeneity. 5 Subgroup analyses and meta-regression models were performed to investigate potential sources of between-study heterogeneity. Small study bias, consistent with publication bias, was assessed with funnel plot, by Begg adjusted rank correlation test and by Egger regression asymmetry test. 6 We used STATA, version 11.0 (Stata Corp), for all analyses. Statistical tests were 2-sided and used a significance level of P<0.05.
Results
Study Selection
With the search strategy, 4326 unique citations were initially retrieved. Finally 72 articles were eligible for inclusion ( Figure 1 ).
Study Characteristics
A total of 33 434 individuals were enrolled in 72 eligible studies, of which 54.8% had an ischemic cause and 24.1% were women. Patients were followed up for an average of >2 years in a majority of studies (64.8%). The proportion of patients with complete follow-up to the end of the study was given for 26 studies and ranged from 70.5% to 100%. The sizes of the cohorts ranged from 21 to 3526, with 8 largest studies recruiting >1000 participants ( Table I in the Data Supplement).
The mean LVEF was consistent across the studies (18-28.4%). Although the minimum duration of QRS interval required for patient enrolment differed between the studies, the mean QRS interval was similar across the studies (146-180 ms).
In 9 studies that reported baseline characteristics of both sex separately, the female patients were more likely to have nonischemic cardiomyopathy and left bundle branch block (LBBB) conduction pattern compared with male patients, whereas men were more likely to have ischemic heart disease and atrial fibrillation compared with women. The patients were well treated with appropriate cardiac medications, but women received more β-blockers and aldosterone antagonist. Mean LVEF, QRS duration, and New York Heart Association class function were not systematically different between women and men (Tables II and III in the Data Supplement) . 4, [7] [8] [9] [10] [11] [12] [13] [14] 
Primary End Point
Forty-five studies with data of 27 547 individuals and at least 6988 events reported sex-stratified relative risk estimates for all-cause mortality. Overall, women receiving CRT had a significantly better outcome compared with men (HR, 0.67; 95% CI, 0.61-0.74; P<0.001; Table 1 ; Figure 2 ). 2,4,7-9,12-51 Risk estimates changed little after analysis with fixed-effect models (HR, 0.70; 95% CI, 0.65-0.74; P<0.001). Further analysis of studies that adjusted for ischemic heart disease or QRS duration also yielded similar results (HR, 0.63; 95% CI, 0.54-0.73; P<0.001). Neither funnel plots nor Egger and Begg tests showed evidence of publication bias (Egger, P=0.49; Begg, P=0.06; Figure IA in the Data Supplement). Kaplan-Meier estimates of the probability of death from any cause for women and men with CRT from 7 studies are shown in Figure 3A (HR, 0.59; 95% CI, 0.50-0.70; P<0.001). Although significant heterogeneity was observed among the 45 available studies (I 2 =29.49%; 95% CI, 0-51.36%; P=0.03), little of it was explained by study design (P=0.20), percentage of women (P=0.64), sample size (P=0.87), number of events (P=0.55), duration of follow-up (P=0.22), average LVEF (P=0.70), whether risk profiles were adjusted (P=0.53), or whether patients with atrial fibrillation were enrolled (P=0.33). There was some evidence that the HR with patient sex differed slightly between European and American cohorts; the HR for the 23 European studies (11 561 patients; 2381 deaths) was 0.57 (95% CI, 0.50-0.65) versus 0.70 (95% CI, 0.58-0.80) in the 13 American studies (5867 patients; 1619 deaths; P=0.04). However, no significant difference was observed between European and Asia cohorts (P=0.12; Figure 4 ).
Secondary End Point
The secondary end point of death or hospitalization for HF occurred in 3649 patients among 12 965 participants from 24 studies. The overall HR of death or HF in women compared with men was 0.80 (95% CI, 0.71-0.90; P<0.001), with no significant between-study heterogeneity (I 2 =17.27%; 95% CI, 0-49.64%; P=0.22; Table 1 ; Figure II in the Data Supplement). There was no evidence of publication bias (Egger, P=0.10; Begg, P=0.69; Figure IB in the Data Supplement). Kaplan-Meier curves for the secondary end point illustrating the impact of sex from 7 studies are presented in Figure 3B (HR, 0.59; 95% CI, 0.51-0.69; P<0.001). In the stratified analyses, no significant heterogeneity by study design, sample size, number of events, average followup, QRS duration, average LVEF, or levels of adjustment was observed. However, the sex-related difference for the secondary end point was more evident in European studies compared with American studies (P=0.03; Figure 5 ).
Cardiac Death, Hospitalization for HF, Ventricular Arrhythmias, or Sudden Cardiac Death
The HRs for cardiac death, cardiac death or hospitalization for HF, HF only, or ventricular arrhythmias or sudden cardiac death in women versus men are presented in Table 1 . Women receiving CRT had a significantly better outcome in cardiac death compared with men (HR, 0.59; 95% CI, 0.42-0.84; P<0.001). Similarly, women appeared to experience a reduced risk of ventricular arrhythmias or sudden cardiac death compared with men (HR, 0.59; 95% CI, 0.49-0.70; P<0.001). For all 2 other outcomes, women also achieved better results from CRT compared with men, and no evidence of significant quantitative heterogeneity was found (Figures III-V in the Data Supplement).
Echocardiographic and Functional Parameters
The changes in echocardiographic and functional parameters between baseline and long-term follow-up for women and men from 6 studies are presented in Table 2 . 4,7-9,36,52
Echocardiographic volumes and EF parameters improved significantly with CRT therapy within both the female and male groups (P<0.05). Women had consistently greater improvements in reverse cardiac remodeling with CRT therapy than did men. Functional status changed considerably with an improvement in exercise tolerance tested by 6-minute walking test, quality of life, and New York Heart Association functional class in both sex (P<0.05 for all). However, absolute changes in functional parameters showed no significant difference between men and women.
Discussion
The present meta-analysis, involving 33 434 patients from 72 studies, found that women had better outcomes from CRT compared with men. Compared with men, women had about a 33% reduction in the risk of death from any cause and 20% reduction in the risk of death or HF. The sex-based difference in response to CRT appeared to be more evident in the subgroup of patients from Europe than patients from America. Further analyses of the end points of cardiac death, hospitalization for HF, and ventricular arrhythmias or sudden cardiac death yield similar results. Women achieved greater reduction in LV volumes and improvement in LVEF compared with men after CRT therapy.
Men and women are known to differ in comorbidities, risk factors, and responses to medical therapy of HF. Recent studies have suggested that women with HF have a somewhat better response to β-blockers, a worse prognosis with digoxin therapy, and a lower survival benefit with implantable cardioverter defibrillators than do men. [53] [54] [55] [56] To our knowledge, this meta-analysis is the first to confirm that female patients with HF derive significantly greater benefit from CRT than do male patients.
The reasons for these differences are still unclear. However, several plausible explanations have been suggested. First, although the overall prevalence of HF is equally distributed between men and women, there exist sex-related differences in modes of death among patients with HF. Female patients appeared to experience more deaths from pump failure and less sudden cardiac deaths compared with male patients. This provides an explanation why women derive relatively more benefit from CRT and less survival benefit from primary prevention of implantable cardioverter defibrillators. 57 Second, women had more nonischemic cause, LBBB, utilization of β-blockers and aldosterone antagonists, which have been associated with better CRT outcomes. 4 The analyses of studies that reported baseline characteristics of both sex also yielded similar results. However, the difference of prognosis still existed in studies that adjusted for the baseline risk profiles, suggesting that the sexrelated difference in response to CRT is independent of baseline characteristics. Third, among healthy subjects, women have smaller LV mass and on average 4 to 10 ms narrower QRS compared with men. 58, 59 Furthermore, with healthy aging, women have higher LVEF compared with men at a given age because of greater age-related LV concentric remodeling. 60, 61 Therefore, female patients may have more conduction disturbance, greater dyssynchrony, and LV systolic dysfunction for the same entry criteria of QRS duration or LVEF. Fourth, CRT therapy has been shown to improve markers of sympathetic drive and reverse cardiac remodeling, 62 which may have a greater therapeutic effect in women independent of baseline characteristics, similar to the well-established benefit of β-blockers in female patients with HF.
There is 1 factor that may confound the interpretation of sexbased differences in the response to CRT therapy. Women have been shown to have a survival advantage compared with men in HF studies, 63 and therefore it is possible that the survival trends observed in our study were related to the intrinsic survival advantage in women rather than the effect of CRT. Nevertheless, our further analysis suggested that women achieved greater reduction in LV volumes and improvement in LVEF compared with men from CRT therapy, indicating that these more favorable results for women were associated with greater improvements in reverse cardiac remodeling in women than in men.
Women with advanced HF have received significantly fewer CRT devices, especially the more expensive and complex CRT defibrillators. 64 Women made up only 24.1% of the overall population in our study. They comprised only 24.4% of the randomized patients and 24.0% of the patients in the registry. Although our data do not evaluate the causes for this sex disparity in the use of CRT devices, there are several possible explanations. Women with HF have more often preserved EF compared with men, and women with reduced EF have better EF, but they tend to have more impaired functional capacity. 65, 66 Therefore, CRT may be underutilized in women with HF according to the current guidelines. In addition, studies of patient attitudes toward device therapy showed higher refusal of device implantation and more concerns for complications in women. Women had a trend toward more adverse events during CRT implantation. 67 It has been speculated that smaller body size and vessel diameter may make women more susceptible to mechanical complications. 68 Furthermore, female patients are often under-referred for procedure by their physicians. Women generally have less specific symptoms of cardiac disease, which results in an underestimation of the severity of HF. 69 Given these findings, it is expected that we focus our attention on a subgroup of women with LVEFs of 35% to 50% and to determine whether CRT could prevent HF events and deaths in this patient group.
Strengths of this meta-analysis include the strict inclusion criteria, the large number of patients analyzed, and diversity of study population. The consistency in study findings, combined with no evidence of important publication bias, supports the robustness of the study findings. One limitation of our study is the heterogeneity among studies in the primary analysis. Although differences in geographical area seem, at least in part, to explain this finding, whether this relates to body size or heart size differences across populations is unknown. Another limitation was the lack of individual participant data, which precluded exploring in depth the interaction of sex and other individual variables that may also influence the outcomes. For example, although LV lead location may influence the outcomes for patients with CRT therapy, it is difficult to perform a sex analysis because of lack of information on LV lead location in women versus men. In addition, LBBB was present in a majority of participants in most studies in light of the current guideline recommendation and women with LBBB appeared to achieve better results compared with men. Hence, it is also possible that sex-based difference in response to CRT observed in our studies may to some extent depend on the positive effects of CRT in LBBB. But limited data on the stratified analysis of patients with LBBB and non-LBBB in the original studies preclude our further sex analysis.
In conclusion, the results of the present meta-analysis suggest that women had greater reductions in the risk of death from any cause, cardiac cause, death or hospitalization for HF, and ventricular arrhythmias or sudden cardiac death compared with men in patients with CRT. Future research should be directed at identifying reasons for these sex disparities and at determining whether indications for CRT for women should be different from men. Δ indicates change in echocardiographic and clinical parameters between baseline and long-term follow-up. LVEDV indicates left ventricular end-diastolic volume; LVESV, LV end-systolic volume; LVEF, LV ejection fraction; NYHA, New York Heart Association; QoL, quality of life; and WCT, 6-min walking test.
Table 2. Changes in Echocardiographic and Clinical Parameters Between Baseline and Long-Term Follow-Up for Cardiac Resynchronization Therapy-Treated Patients by Sex From 6 Studies
